Bioheart Receives Validated FDA Registration for Tissue Bank Establishment

SUNRISE, FL--(Marketwired - Aug 9, 2013) - Bioheart, Inc. (OTCQB: BHRT) announced today that it received a validated registration from the FDA for the initial tissue bank listing.Bioheart is offering stem cell storage for patients enrolled in the studies at the centers of excellence outside the US.This new business unit will create an additional revenue stream for Bioheart.Patients can store stem cell doses in liquid nitrogen for future use in approved clinical trials.These trials focus on the use of LipiCell (adipose derived stem cells) in a variety of different degenerative diseases.

Kristin Comella, Chief Science Officer, commented, "The expansion of the Bioheart facilities to include cryopreservation will bring additional revenue to the company and offer patients more options in the emerging field of regenerative medicine.Patients are able to utilize cells at a later date without additional invasive collection procedures."

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues.Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2012, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013.

Originally posted here:
Bioheart Receives Validated FDA Registration for Tissue Bank Establishment